1441TiP An open-label, phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852)
Saved in:
| Title: | 1441TiP An open-label, phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852) |
|---|---|
| Authors: | Laban, S.1 (AUTHOR), Osinowo, S.2 (AUTHOR), Hu, C.3 (AUTHOR), Tosiek, M.4 (AUTHOR), Pronk, L.C.5 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS874-S875. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
